Cord Blood Stem Cells Market is estimated to reach USD 9.77 billion by 2030 : Cognitive Market Research

Market Overview:
- Cord blood is the blood that stays in the baby's placenta and umbilical cord after birth. It is quite simple to gather and poses no danger to the mother or baby. Cord blood contains a high concentration of stem cells, which can be utilized to treat a variety of malignancies, immunological deficiencies, and genetic abnormalities. Cord blood is remained in the umbilical cord and placenta after a baby is delivered.

Summary:
- The cord blood stem cells market is expected to grow from USD 3.93 billion in 2022 to USD 9.77 billion by 2030, at a CAGR of 12.04%. Currently, the demand for cord blood stem cells gaining momentum due to the rising research activities, increasing birth rate, rising prevalence of rare diseases, and others.

"To know more The Cord Blood Stem Cells Market statistics click here: https://www.cognitivemarketresearch.com/cord-blood-stem-cells-market-report

Market Dynamics:
- Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. The most common in 2020 (in terms of new cases of cancer) were: breast (2.26 million cases), lung (2.21 million cases), colon (1.93 million cases), prostate (1.41 million cases), skin (non-melanoma) (1.20 million cases), and stomach (1.09 million cases). The rising cases of cancers raise the demand for the cord blood stem cell market.
However, the cost structure of stem cell therapy may stifle industry expansion. Nonetheless, innovative treatments based on stem cells derived from cord blood and cord tissue are being tested in clinical trials for the treatment of chronic and life-threatening disorders like as autism, cerebral palsy, multiple sclerosis, traumatic brain injury, stroke, and many more. With FDA clearance, these therapies can subsequently be used on a regular basis. This factor is projected to give tremendous prospects for market expansion.

Market Segmentation:
Type:
• Allogeneic Stem Cell
• Autologous Stem Cell
Based on type, the allogeneic stem cell segment dominates the market growth as the transplant has a lower risk of life-threatening complications.

Storage Service:
• Public Cord Blood Banks
• Private Cord Blood Banks
• Hybrid Cord Blood Banks
Based on storage service, the private cord banks segment dominates the market growth due to the rising number of private cord banks growing across the globe.

Application:
• Cancer
• Diabetes
• Blood diseases
• Immune Disorders
• Metabolic Disorders
• Others
Based on applications, the diabetes segment dominates the market growth. Coed blood cells have a higher amount of regulatory T cells, a kind of white blood cell that helps to keep the immune system in check. As a result, cord blood stem cells may be effective in treating disorders in which the immune system has "gone astray," such as type 1 diabetes.

The Major Players in Cord Blood Stem Cells Market are:
Advanced Cell Technology, California Stem Cell, Cytori Therapeutics, Mesoblast Limited, Opexa Therapeutics Inc., Athersys Inc., Geron Corporation, Neostem Inc., CBR Systems Inc., Cordlife, Cryo Cell, Cryo Save AG A Group of Esperite, Lifecell, Stemcyte, Viacord, Smart Cells International Ltd., Cryoviva India, Cordvida, China Cord Blood Corporation

Get free sample pages of latest published Cord Blood Stem Cells Report:
https://www.cognitivemarketresearch.com/cord-blood-stem-cells-market-report#request_sample

Regional Analysis:
- The global cord blood stem cells market is geographically divided into regions like North America, Europe, Asia Pacific, Latin America, and Middle-east Countries. North America dominates the cord blood stem cells market owing to the rising number of cord banks, rising healthcare expenditure, growth in pregnant women, and others.

News:
- In April 2022, Global Cord Blood Corporation announced that it will acquire 100% of Cellenkos, Inc ("CLNK") as well as the rights to develop and sell all of CLNK's present and future products globally, with the exception of those relating to CLNK's current partnership with Incyte Corporation. The Company has entered into agreements with the holders of roughly 95% of CLNK's outstanding equity interest and GM Precision Medicine (BVI) Limited as of the date hereof ("GMPM"). Following the execution of a similar agreement with the remaining 5% holder, the Company will issue approximately 125 million new shares (on an as-converted and fully diluted basis) priced at US$11 per share and pay US$664 million in cash as total consideration at the close.

Browse here for Full TOC:
Table of Content (Revenue USD Edition), (Enquire about Volume/Consumption Edition Data)
Chapter 1 Industrial Insight and Market Scope
• 1.1 Global Cord Blood Stem Cells Industry Introduction
• 1.2 Objectives of the Study
• 1.3 USP of the Report
• 1.4 Who is this report for?
• 1.5 Designing of Market Scope
o 1.5.1 Segmentation
o 1.5.1 Regional Fragmentation
o 1.5.1 Market Players
• 1.6 Report Duration
Chapter 2 Research Methodology
Chapter 3 Executive Summary
Chapter 4 Global Cord Blood Stem Cells Market Overview
• 4.1 Introduction
• 4.2 Global Cord Blood Stem Cells Market Statistics by Regions (2018-2030)
4.2.1 North America Cord Blood Stem Cells Status and Prospect (2018-2030)
4.2.2 Europe Cord Blood Stem Cells Status and Prospect (2018-2030)
4.2.3 Asia Pacific Cord Blood Stem Cells Status and Prospect (2018-2030)
4.2.4 Latin America Cord Blood Stem Cells Status and Prospect (2018-2030)
4.2.5 Middle East and Africa Cord Blood Stem Cells Status and Prospect (2018-2030)
Chapter 5 Competitive Analysis (Subject to Availability)
Chapter 6 Qualitative Analysis
Chapter 7 Company Profiling (Subject to Availability)
Chapter 8 Global Cord Blood Stem Cells Market by Type Segmentation Analysis (2018-2030)
Chapter 9 Global Cord Blood Stem Cells Market by Application Segmentation Analysis (2018-2030)
Chapter 10 Global Cord Blood Stem Cells Market by Storage Service Segmentation Analysis (2018-2030)
Chapter 11 Global Cord Blood Stem Cells Market Regional Analysis
Chapter 12 North America Cord Blood Stem Cells Market Outlook (2018 - 2030)
Chapter 13 Europe Cord Blood Stem Cells Market Outlook (2018 - 2030)
Chapter 14 Asia Pacific Cord Blood Stem Cells Market Outlook (2018 - 2030)
Chapter 15 Latin America Cord Blood Stem Cells Market Outlook (2018 - 2030)
Chapter 16 Middle East and Africa Cord Blood Stem Cells Market Outlook (2018 - 2030)
Chapter 17 Research Findings

To know more Cord Blood Stem Cells Market TOC click here: https://www.cognitivemarketresearch.com/cord-blood-stem-cells-market-report#table_of_contents

Related Reports:
• Cord Blood Bank Market - https://www.cognitivemarketresearch.com/cord-blood-bank-market-report
• Stem Cell Market - https://www.cognitivemarketresearch.com/stem-cell-market-report
• Hematopoietic Stem Cell Transplantation (HSCT) Market - https://www.cognitivemarketresearch.com/hematopoietic-stem-cell-transplantation-%28hsct%29-market-report
• Mesenchymal Stem Cells Market - https://www.cognitivemarketresearch.com/mesenchymal-stem-cells-market-report

𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐔𝐬
Nicolas Shaw
Cognitive Market Research
20 N State Street,Chicago,
Illinois, 60602
United States
USA: +1 312-376-8303
Europe and UK: (+44) 20-8144-9523
Asia Pacific: (+852) 81930785
Email: sales@cognitivemarketresearch.com
Website: https://www.cognitivemarketresearch.com/about-us

About Cognitive Market Research Company :
Cognitive Market Research has evolved as one leading market research and consulting firm and it provides services across multiple domains. Cognitive Market Research gathers and analyzes data about customers, competitors, distributors, and other market actors and forces operational across the value chain. As a market research company, we follow a complete process of gathering information about the target market and end-use industries to verify the complete journey of the product or service in the global market. It helps our readers understand the demand and viability of their product/service and how it might perform in the real world and help them to build business strategies accordingly.

This release was published on openPR.